Shelf life (days): 1460.0
Formulation: A solid
Formal Name: N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6-methyl-8-(methyl-13C-d3)-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-acetamide
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C25[13C]H20D3FIN5O4
Formula Weight: 619.4
CAS Number: 2712126-59-3
Notes: Trametinib-13C-d3 is intended for use as an internal standard for the quantification of trametinib (Item No. 16292) by GC- or LC-MS. Trametinib is an inhibitor of MEK1 and -2.{46450} It inhibits B-RAF- and C-RAF-induced phosphorylation of MEK1 (IC50s = 3.4 and 1.8 nM, respectively) and MEK2 (IC50s = 1.6 and 0.92 nM, respectively). Trametinib inhibits the growth of two human colorectal cancer cell lines expressing mutant B-RAF (IC50s = 0.48 and 0.52 nM) and seven cell lines expressing mutant K-Ras (IC50s = 2.2-174 nM) but does not inhibit the growth of wild-type COLO 320DM cells expressing both B-RAF and K-Ras (IC50 = >10,000 nM). It reduces tumor growth in HT-29 and COLO 205 mouse xenograft models when used at doses of 0.3 and 1 mg/kg per day. Trametinib (0.03 and 0.1 mg/kg per day) also decreases M. tuberculosis-induced increases in hind paw volume in a rat model of arthritis.{46451} Formulations containing trametinib, in combination with dabrafenib, have been used in the treatment of B-RAFV600E mutant metastatic melanoma.
English
Deutsch
